ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2025

Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study.

Martin Schiestl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.